Latest Articles
KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer - Indian Pharma Post
KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer Indian Pharma Post
Published: Oct. 22, 2025, 5:03 p.m.
Nearly half of endometrial cancer patients respond to Rina-S in trial - Rare Cancer News
Nearly half of endometrial cancer patients respond to Rina-S in trial Rare Cancer News
Published: Oct. 22, 2025, 1:31 p.m.
Overcoming the Complexity of Total Laparoscopic Hysterectomy and Bilateral Salpingo-Oophorectomy in a Patient With Uterine Didelphys and Dual Endometrial Pathology: A Surgical Approach in a Complex Anatomical Variant - Cureus
Overcoming the Complexity of Total Laparoscopic Hysterectomy and Bilateral Salpingo-Oophorectomy in a Patient With Uterine Didelphys and Dual Endometrial Pathology: A Surgical Approach in a Complex Anatomical Variant Cureus
Published: Oct. 22, 2025, 3:01 a.m.
Adiposity, Metabolites Linked to Endometrial Cancer - bioengineer.org
Adiposity, Metabolites Linked to Endometrial Cancer bioengineer.org
Published: Oct. 21, 2025, 2:27 p.m.
Adiposity, Metabolites Linked to Endometrial Cancer - Bioengineer.org
Adiposity, Metabolites Linked to Endometrial Cancer Bioengineer.org
Published: Oct. 21, 2025, 2:27 p.m.
Adiposity, Metabolites Linked to Endometrial Cancer - BIOENGINEER.ORG
Adiposity, Metabolites Linked to Endometrial Cancer BIOENGINEER.ORG
Published: Oct. 21, 2025, 2:27 p.m.
Comparison of identification of sentinel lymph nodes between ICG vs methylene blue in v notes staging surgery for endometrial cancer - BMC Surgery
Comparison of identification of sentinel lymph nodes between ICG vs methylene blue in v notes staging surgery for endometrial cancer BMC Surgery
Published: Oct. 21, 2025, 11:10 a.m.
Dana-Farber Research Uncovers Potential Targeted Therapy for Endometrial Cancer - Dana-Farber Cancer Institute
Dana-Farber Research Uncovers Potential Targeted Therapy for Endometrial Cancer Dana-Farber Cancer Institute
Published: Oct. 21, 2025, 9 a.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - BioSpace
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer BioSpace
Published: Oct. 21, 2025, 5:15 a.m.
KEYNOTE-755 Confirms Broad Efficacy of Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer - Pharmacy Times
KEYNOTE-755 Confirms Broad Efficacy of Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer Pharmacy Times
Published: Oct. 21, 2025, 3:34 a.m.
Link copied to clipboard!